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= 0.557, p < 0.0001) users were signiﬁcantly less likely to be
over-adherent. CONCLUSION: Over one-half of central Texas
veterans were over-adherent with their antipsychotic therapy.
Further studies are warranted to determine the impact of exces-
sive medication possession on patient outcomes as well as the
economic impact on the VA system.
PMH60
ANALYSIS OF LONGITUDINAL CLAIMS DATA TO EXAMINE
FIRST AND SECOND-LINE USE OF PEMOLINE (CYLERT®)
Morrato E1, Staffa J2
1Johns Hopkins University Bloomberg School of Public Health (FDA
student project), Baltimore, MD, USA; 2Food and Drug
Administration, Rockville, MD, USA
OBJECTIVE: Pemoline, a CNS stimulant, is approved for Atten-
tion Deﬁcit and Hyperactivity Disorder (ADHD). In practice, it’s
additionally used to treat narcolepsy and MS-related fatigue.
Because pemoline was associated with acute liver failure, FDA
relabeled its use as ‘second-line’ therapy (SLT) for ADHD in
1996. This retrospective observational study examines longitu-
dinal prescription records suggestive of ﬁrst or second-line use
to describe apparent compliance with relabeling and factors
associated with second-line use. METHODS: Prescription claims
from a continuously-enrolled population (September 1, 2000—
September 30, 2002) from AdvancePCS pharmacy beneﬁt
manager (PBM) were evaluated for patients with 1 or more
pemoline claims. Patients were categorized using pemoline as
SLT or ‘ﬁrst-line’ therapy (FLT) depending on presence/absence
of other CNS stimulant prescriptions 90 days prior to the ﬁrst
pemoline claim. Chi-square compared SLT and FLT patients with
regard to age, gender and prescribing physician specialty.
RESULTS: Of 50M covered lives, 2320 had pemoline claims:
51% male, 34% age 0–19 years. 22% used pemoline as SLT
(95% CI: 19%–24%). Children <20 years were more likely to
use pemoline as SLT (40%) than adults >19 years (14%) (p <
0.001). Across all ages, males were more likely to use pemoline
as SLT (27%) than females (17%) (p < 0.001). Physician spe-
cialty was associated with SLT (p < 0.001): pediatrics (43%),
psychiatry (32%), primary care (22%), and neurology (5%).
CONCLUSIONS: Most patients in a large PBM appear to use
pemoline without antecedent prescriptions for other CNS stim-
ulants, a prescribing pattern inconsistent with FDA-approved
SLT labeling. Although ADHD summertime “drug holidays”
>90 days may have inﬂated estimates of FLT that was actually
SLT, children had higher levels of SLT than adults. FDA’s label-
ing action may have affected approved ADHD usage (pre-
dominantly male pediatric patients) more than off-label
narcolepsy/MS usage (older neurology patients). These results in
a large patient population are consistent with earlier, smaller
studies.
PMH61
TRENDS IN ANTIPSYCHOTIC PRESCRIBING TO CHILDREN
AND ADOLESCENTS: 1996 TO 2001
Patel NC1, Crismon ML1, Hoagwood K2, Johnsrud MT1, Rascati K1,
Wilson JP1
1The University of Texas at Austin, Austin,TX, USA; 2Columbia
University, New York, NY, USA
OBJECTIVES: The purpose of this study was to examine trends
in antipsychotic use in children and adolescents enrolled in three
Medicaid programs (a Midwestern [MM], Southern [SM], and
Western [WM] state) or a national private managed-care orga-
nization (MCO). METHODS: Antipsychotic prevalence was
deﬁned as the number of individuals under the age of 20 years
with at least one prescription claim for an antipsychotic agent,
regardless of subclass, per 1000 enrolled children and adoles-
cents. Total, antipsychotic subclass, age-speciﬁc, and gender-
speciﬁc prevalence rates of antipsychotic use from 1996 to 2001
were estimated. Time trends of antipsychotic prevalence esti-
mates were assessed. RESULTS: From 1996 to 2001, the preva-
lence of total antipsychotic use increased in each insurance
program (MM: +9.6 per 1000, odds ratio [OR] 1.24; SM: +9.2,
OR 1.19; WM: +2.4, OR 1.10; and, MCO: +2.0, OR 1.24). The
prevalence of typical antipsychotic use decreased (prevalence
ratios [2001 :1996] 0.29 to 0.72; OR 0.78 to 0.98), while the
prevalence of atypical antipsychotics dramatically increased
(prevalence ratios 5.99 to 19.73; OR 1.35 to 1.56). Across all
systems, the use of antipsychotics increased in children and ado-
lescents above the age of 5 years. Male and female antipsychotic
prevalence rates also increased. Antipsychotic usage was highest
in SM, followed by MM, WM, and MCO. CONCLUSIONS: In
all 4 programs, the prevalence of antipsychotic use in children
and adolescents increased signiﬁcantly from 1996 to 2001. This
is attributed to the increased use of atypical antipsychotics. Geo-
graphic and health system variations in antipsychotic prescribing
existed. Given the limited efﬁcacy and safety data with antipsy-
chotics in children and adolescents, this raises questions about
appropriate use and emphasizes the need for additional studies
of atypical antipsychotics in this population.
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OBJECTIVES: Determine whether there was a reduction in hos-
pital utilization following the implementation of an open access
policy for atypical antipsychotic medications for a publicly
funded drug program in Newfoundland and Labrador.
METHODS: The inpatient records of patients discharged from
hospital in 1995/96, 1998 and 2000 with an ICD-9 diagnosis of
schizophrenia were reviewed to determine the factors inﬂuenc-
ing total days hospitalization and readmission rates. Cox pro-
portional hazards models were used to identify factors associated
with LOS and logistic regression to determine early readmission.
RESULTS: Six hundred forty-ﬁve patients admitted in 3 study
years had 1,625 episodes of care totaling 47,098 days. The
number of hospital days increased by 1229 days in 1998 and
602 days in 2000 when compared to baseline (1995/96). The
study populations were similar with respect to sociodemographic
factors, psychiatric status and level of care provided. The pro-
portion of patients discharged on an atypical agent from an
index admission increased from 15% at baseline to 71% in the
ﬁnal year and the average LOS increased from 31 days to 39
days. Requiring electroconvulsive therapy (ECT), switching from
a conventional antipsychotic to an atypical agent during the
admission, requiring seclusion, or having thought disorder was
independently associated with a signiﬁcantly longer LOS.
Leaving against medical advice (AMA), or being suicidal on
admission decreased hospitalization. Fifty percent of the popu-
lation was readmitted in 215 days in 1995/96, 221 days in 1998,
and 223 days in 2000. Independent of the class of antipsychotic
prescribed on last discharge, leaving AMA and number of pre-
vious admissions signiﬁcantly increased the risk of readmission
within 1 year. CONCLUSIONS: The number of patients with
schizophrenia admitted to hospital decreased but the LOS
increased with no change in readmission rates. The expectations
that the associated higher costs would be offset by decreased hos-
pitalization for schizophrenia were not achieved.
